Omalizumab use while Breastfeeding

Drugs containing Omalizumab: Xolair

Omalizumab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of omalizumab during breastfeeding. Because omalizumab is a large protein molecule with a molecular weight of 145,058, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, omalizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

Omalizumab Identification

Substance Name

Omalizumab

CAS Registry Number

242138-07-4

Drug Class

Anti-Allergic Agents

Anti-Asthmatic Agents

Antibodies, Monoclonal

Antibodies, Anti-Idiotypic

Administrative Information

LactMed Record Number

890

Last Revision Date

20130907

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide
(web5)